Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients

被引:9
|
作者
Macedo, Luciana Conci [1 ]
Quintero, Fernanda de Cesare [2 ]
Pagliari-E-Silva, Sara [3 ]
Barbosa Pagnano, Katia Borgia [4 ]
Rodrigues, Camila [1 ]
de Alencar, Josiane Bazzo [1 ]
Sell, Ana Maria [2 ]
Laguila Visentainer, Jeane Eliete [2 ]
机构
[1] Univ Estadual Maringa, Biomed & Clin Anal Dept, Post Grad Program Biosci & Physiopathol, BR-87020900 Maringa, Parana, Brazil
[2] Univ Estadual Maringa, Basic Hlth Sci Dept, Ave Colombo 5790, BR-87020900 Maringa, Parana, Brazil
[3] Hosp Canc Maringa, Maringa, Parana, Brazil
[4] Univ Estadual Campinas, Ctr Hematol & Hemoterapia Campinas, Sao Paulo, Brazil
关键词
Myeloproliferative disorders; NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISM; GENETIC POLYMORPHISMS; POLYCYTHEMIA-VERA; SUSCEPTIBILITY; LUNG; REGION;
D O I
10.1016/j.bcmd.2015.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The classical chromosome Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of disorders that share clinical, hematological, and histological features. Proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) are elevated in patients with MPN. The aim of this study was to verify the association between the polymorphisms of TNF gene (-308G/A and-238 G/A) in BCR-ABL-negative MPN in our population. Blood samples obtained from MPN patients were genotyped for the JAK2V617F mutation and both TNF polymorphisms using PCR-RFLP. Thirty three (26.8%) patients with polycythemia vera (PV), 35 (28.7%) essential thrombocythemia (ET), 22 (17.7%) primary myelofibrosis (PMF), and 33 (26.8%) with unclassifiable MPN (MPNu) were included in the study. The JAK2 V617F mutation was detected in 94 (76.42%) patients. Were observed a significant increase on the frequency of the TNF-238 GA genotype in MPN patients compared to controls (OR = 221, 95% Cl = 1.02-4.80, P < 0.04). The distribution of the genotypes and allelic frequencies of TNF-308 was significantly different among the MPNs, JAK2V617F positive, PV and PMF, and controls. Our data has demonstrated that the polymorphisms on TNF-238 GA, TNF-308 GA were associated to MPN development in this population, triggered by JAK2 V617F mutation. (C) 2015 Published by Elsevier Inc.
引用
收藏
页码:54 / 57
页数:4
相关论文
共 50 条
  • [21] Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
    Benati, Marco
    Montagnana, Martina
    Danese, Elisa
    De Matteis, Giovanna
    Veneri, Dino
    Paviati, Elisa
    Guidi, Gian Cesare
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (07) : 1005 - 1011
  • [22] Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms
    Mambet, Cristina
    Babosova, Olga
    Defour, Jean-Philippe
    Leroy, Emilie
    Necula, Laura
    Stanca, Oana
    Tatic, Aurelia
    Berbec, Nicoleta
    Coriu, Daniel
    Belickova, Monika
    Kralova, Barbora
    Lanikova, Lucie
    Vesela, Jitka
    Pecquet, Christian
    Saussoy, Pascale
    Havelange, Violaine
    Diaconu, Carmen C.
    Divoky, Vladimir
    Constantinescu, Stefan N.
    BLOOD, 2018, 132 (25) : 2695 - 2699
  • [23] JAK out of the box: myeloproliferative neoplasms-associated JAK2 V617F mutations contribute to aortic aneurysms
    Elf, Shannon E.
    HAEMATOLOGICA, 2021, 106 (07) : 1783 - 1784
  • [24] Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR
    Waterhouse, Miguel
    Follo, Marie
    Pfeifer, Dietmar
    von Bubnoff, Nikolas
    Duyster, Justus
    Bertz, Hartmut
    Finke, Juergen
    ANNALS OF HEMATOLOGY, 2016, 95 (05) : 739 - 744
  • [25] Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
    Bench, Anthony J.
    White, Helen E.
    Foroni, Letizia
    Godfrey, Anna L.
    Gerrard, Gareth
    Akiki, Susanna
    Awan, Abida
    Carter, Ian
    Goday-Fernandez, Andrea
    Langabeer, Stephen E.
    Clench, Tim
    Clark, Jordan
    Evans, Paul A.
    Grimwade, David
    Schuh, Anna
    McMullin, Mary F.
    Green, Anthony R.
    Harrison, Claire N.
    Cross, Nicholas C. P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (01) : 25 - 34
  • [26] Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms
    Lee, Eunyoung
    Lee, Kyoung Joo
    Park, Hyein
    Chung, Jin Young
    Lee, Mi-Na
    Chang, Myung Hee
    Yoo, Jongha
    Lee, Hyewon
    Kong, Sun-Young
    Eom, Hyeon-Seok
    ANNALS OF LABORATORY MEDICINE, 2018, 38 (02) : 147 - 154
  • [27] Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms
    Za, Tommaso
    Fiorini, Alessia
    Rossi, Elena
    Ciminello, Angela
    Chiusolo, Patrizia
    Leone, Giuseppe
    De Stefano, Valerio
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) : 965 - 967
  • [28] JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
    Reis Monte-Mor, Barbara da Costa
    da Cunha, Anderson Ferreira
    Barbosa Pagnano, Katia Borgia
    Saad, Sara Terezinha
    Lorand-Metze, Irene
    Costa, Fernando Ferreira
    GENETICS AND MOLECULAR BIOLOGY, 2007, 30 (02) : 336 - 338
  • [29] JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients
    Tanaka, Mayumi
    Yujiri, Toshiaki
    Ito, Shunsuke
    Okayama, Naoko
    Takahashi, Toru
    Shinohara, Kenji
    Azuno, Yoichi
    Nawata, Ryouhei
    Hinoda, Yuji
    Tanizawa, Yukio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (03) : 409 - 413
  • [30] Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F
    Gattenlohner, S.
    Serfling, E.
    Einsele, H.
    Mueller-Hermelink, H. K.
    LEUKEMIA, 2009, 23 (01) : 196 - 199